Paris: Sanofi and Regeneron has announced that the US Food and Drug Administration (FDA) has accepted for review the ...

US FDA accepts for review the resubmission of sBLA for Dupixent to treat chronic spontaneous urticaria: Paris Monday, November 18, 2024, 11:00 Hrs [IST] The US Food and Drug Admin ...

Aging is undoubtedly a natural part of life, and while some embrace what time does to their skin, others might look for a little something to smooth out those effects. One popular item that shoppers ...

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore ...

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License ...

SBLA’s Liquid Facelift Wand Line Relaxing Complex eliminates fine lines, deep lines, and wrinkles while visibly plumping skin, and contouring the face. After years of research and formulation ...

Zai Lab and argenx have announced receipt of approval from the National Medical Products Administration (NMPA) of China for ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by ...

The resubmitted sBLA will include results from Study C, which evaluated biologic-naive patients with uncontrolled CSU on antihistamines.